Aligos Therapeutics, Inc (ALGS)

Etorro trading 970x250
Aligos Therapeutics, Inc (ALGS) Logo

About Aligos Therapeutics, Inc

Aligos Therapeutics, Inc., a biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. Its lead drug candidate is ALG-010133, a synthetic oligonucleotide that is in Phase I clinical trial for the treatment of chronic hepatitis B (CHB). The company is also developing ALG-000184, a capsid assembly modulator to treat CHB; ALG-020572, a oligonucleotide for the treatment of CHB; ALG-125097, an siRNA drug candidate to treat CHB; and ALG-055009, a small molecule THR-ß agonist for the treatment of non-alcoholic steatohepatitis. Aligos Therapeutics, Inc. was founded in 2018 and is headquartered in South San Francisco, California. Address: One Corporate Drive, South San Francisco, CA, United States, 94080

Aligos Therapeutics, Inc News and around…

Latest news about Aligos Therapeutics, Inc (ALGS) common stock and company :

NASDAQ: ALGS Shareholder Notice: Investigation over Potential Securities Laws Violations by Aligos Therapeutics, Inc.
24 Jan, 2022 FinancialContent

San Diego, CA -- (SBWIRE) -- 01/24/2022 -- An investigation for investors in Aligos Therapeutics, Inc. (NASDAQ: ALGS) shares over potential securities laws violations by Aligos Therapeutics, Inc. was announced.

ALIGOS ALERT: Bragar Eagel & Squire, P.C. is Investigating Aligos Therapeutics, Inc. on Behalf of Aligos Stockholders and Encourages Investors to Contact the Firm
22 Jan, 2022 FinancialContent

Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Aligos Therapeutics, Inc. (“Aligos” or the “Company”) (NASDAQ: ALGS) on behalf of Aligos stockholders. Our investigation concerns whether Aligos has violated the federal securities laws and/or engaged in other unlawful business practices.

SHAREHOLDER ALERT: Robbins LLP Investigates Aligos Therapeutics, Inc. (ALGS) on Behalf of Shareholders
20 Jan, 2022 FinancialContent

Aligos Therapeutics, Inc. (ALGS) Halted Development of its Lead Drug Candidate

We Think Aligos Therapeutics (NASDAQ:ALGS) Needs To Drive Business Growth Carefully
18 Jan, 2022 Yahoo! Finance

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...

Biotech's virtual JPM conference was a big deal. But, actually, there wasn't one
14 Jan, 2022 Yahoo! Finance

Gilead's cancer ambitions, drug makers continue to mine Covid-19 and potential HIV breakthroughs in a wrap-up of the 40th annual J.P. Morgan Healthcare Conference.

10 Biotech Stocks To Buy According To Chinese Billionaire Lei Zhang
12 Jan, 2022 Yahoo! Finance

In this article, we discuss 10 biotech stocks to buy according to Chinese billionaire Lei Zhang. If you want to skip our detailed analysis of these stocks, go directly to 5 Biotech Stocks To Buy According To Chinese Billionaire Lei Zhang. Hillhouse Capital Management was founded by Chinese billionaire investor and hedge fund manager Lei […]

Aligos Therapeutics Expands Collaboration with Merck to Develop Oligonucleotide Therapies for NASH
11 Jan, 2022 Yahoo! Finance

SOUTH SAN FRANCISCO, Calif., Jan. 11, 2022 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS) a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced that it has expanded its ongoing collaboration agreement with Merck to discover and develop oligonucleotide therapies for non-alcoholic steatohepatitis (NASH). “We believe that one of our strengths as a company is our technical know-how

12 Health Care Stocks Moving In Tuesday's Pre-Market Session
11 Jan, 2022 FinancialContent

Gainers Black Diamond Therapeutic (NASDAQ:BDTX) stock increased by 18.2% to $5.32 during Tuesday's pre-market ...

The Week Ahead In Biotech (Jan 10-15): JPMorgan Healthcare Conference Front And Center, Preannouncements Keep Coming
10 Jan, 2022 FinancialContent

Biotech stocks came under selling pressure along with the broader market, as rate hike fears seized Wall Street. The news flow, however, ...

56 Biggest Movers From Friday
10 Jan, 2022 FinancialContent

Gainers Hour Loop, Inc.(NASDAQ: HOUR) shares jumped 99.8% to $7.99after the company priced its IPO at $4 per ...

12 Health Care Stocks Moving In Friday's Intraday Session
07 Jan, 2022 FinancialContent

Gainers Absci (NASDAQ:ABSI) stock increased by 28.2% to $7.87 during Friday's regular session. As of 12:30 EST, ...

Aligos (ALGS) Stock Down on Hepatitis Drug Development Halt
07 Jan, 2022 Yahoo! Finance

Aligos Therapeutics' (ALGS) phase I study evaluating its chronic hepatitis B candidate, ALG-010133, did not achieve sufficient activity against the disease.

33 Stocks Moving In Friday's Mid-Day Session
07 Jan, 2022 FinancialContent

Gainers Marin Software Incorporated (NASDAQ: MRIN) shares climbed 35.9% to $4.6899 after the company announced an integration with ...

Stocks That Hit 52-Week Lows On Friday
07 Jan, 2022 FinancialContent

Before 10 am on Friday, 110 companies set new 52-week lows. Interesting Points From Today's 52-Week Lows: Humana ...

Benzinga's Top Ratings Upgrades, Downgrades For January 7, 2022
07 Jan, 2022 FinancialContent

Upgrades According to Wolfe Research, the prior rating for CVR Energy Inc (NYSE:CVI) was changed from Peer Perform to ...

58 Biggest Movers From Yesterday
07 Jan, 2022 FinancialContent

Gainers Eargo, Inc. (NASDAQ: EAR) shares climbed 59.7% to close at $7.28 on Thurs after the company announced the Department of ...

Why Aligos Therapeutics Stock Crumbled Today
06 Jan, 2022 FinancialContent

The company is pulling the plug on a once-promising treatment targeting hepatitis B.

Peninsula biotech sheds half its value, ditches hepatitis B program after clinical failure
06 Jan, 2022 Yahoo! Finance

The company went public in October 2020 and has programs in its pipeline that take different approaches to defeating the hepatitis B virus.

Mid-Afternoon Market Update: Gold Drops 2%; Berkeley Lights Shares Plummet
06 Jan, 2022 FinancialContent

Toward the end of trading Thursday, the Dow traded down 0.35% to 36,278.43 while the NASDAQ rose 0.22% to 15,133.94. The S&P ...

12 Health Care Stocks Moving In Thursday's Intraday Session
06 Jan, 2022 FinancialContent

Gainers Eargo (NASDAQ:EAR) stock increased by 50.0% to $6.84 during Thursday's regular session. The current volume ...

Mid-Day Market Update: Nasdaq Turns Higher; Vocera Communications Shares Surge
06 Jan, 2022 FinancialContent

Midway through trading Thursday, the Dow traded down 0.34% to 36,284.59 while the NASDAQ rose 0.18% to 15,127.00. The S&P, however, ...

33 Stocks Moving In Thursday's Mid-Day Session
06 Jan, 2022 FinancialContent

Gainers Eargo, Inc. (NASDAQ: EAR) shares jumped 50.8% to $6.88 after the company announced the Department of Justice confirmed to ...

Aligos Therapeutics Halts Development of Hepatitis B Drug
06 Jan, 2022 Yahoo! Finance

By Sam Boughedda

Mid-Morning Market Update: Markets Open Lower; Walgreens Tops Q1 Views
06 Jan, 2022 FinancialContent

Following the market opening Thursday, the Dow traded down 0.52% to 36,217.32 while the NASDAQ fell 1.09% to 14,935.90. The S&P also ...

Aligos Halting Further Development of STOPS™ Drug Candidate, ALG-010133
06 Jan, 2022 Yahoo! Finance

Phase 1 data at projected efficacious dose (400 mg) indicate insufficient activity against hepatitis B virus to justify further developmentSOUTH SAN FRANCISCO, Calif., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced that it has halted further development of its STOPS™ drug candidate, ALG-010133, in development

Aligos Therapeutics Becomes Oversold (ALGS)
05 Jan, 2022 FinancialContent

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100..

Aligos Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference
21 Dec, 2021 Yahoo! Finance

SOUTH SAN FRANCISCO, Calif., Dec. 21, 2021 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced that Lawrence M. Blatt, Ph.D., MBA, Chairman and CEO of Aligos, will present at the 40th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12, 2022 at 5:15 pm ET. Both the presentation and the Q&A session will be held virt

Analysts Predict 28% Upside For VTWO
21 Dec, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Vanguard Russell 2000 ETF (VTWO), we found that the implied analyst target price for the ETF based upon its underlying holdings is $109.76 per unit.

Aligos Therapeutics Begins Dosing with NASH Drug Candidate, ALG-055009, in Healthy Volunteers in a Phase 1 First-in-Human Study
09 Dec, 2021 Yahoo! Finance

SOUTH SAN FRANCISCO, Calif., Dec. 09, 2021 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced that the company has started dosing in the first cohort of healthy volunteers in Study ALG-055009-301 (NCT05090111). The trial is evaluating Aligos’ thyroid hormone receptor beta (THR-b) agonist drug candidate, ALG-055009, for the trea

Aligos Presents Update of Chronic Hepatitis B Pipeline Portfolio at HEP DART 2021
07 Dec, 2021 Yahoo! Finance

New data from HBeAg-positive patients receiving 100 mg of ALG-000184 demonstrates similar PK and potent antiviral activity to previously reported data for HBeAg-negative patients New preclinical data with a novel oral small molecule PD-1/PD-L1 antagonist shows potential to induce immune responses that together with HBsAg reduction and inhibition of viral replication could provide a multifactorial combination approach to achieve functional cure in CHB patients SOUTH SAN FRANCISCO, Calif., Dec. 07

Aligos Therapeutics, Inc (ALGS) is a NASDAQ Common Stock listed in , ,

970x250